Repro Historical Income Statement

KRMD Stock  USD 2.89  0.02  0.70%   
Historical analysis of Repro Med income statement accounts such as Gross Profit of 16.6 M can show how well Repro Med Systems performed in making a profits. Evaluating Repro Med income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Repro Med's future profits or losses.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Repro Med Systems latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Repro Med Systems is a good buy for the upcoming year.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

About Repro Income Statement Analysis

Repro Med Systems Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Repro Med shareholders. The income statement also shows Repro investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Repro Med Income Statement Chart

At present, Repro Med's Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 16.6 M, whereas Operating Income is projected to grow to (9.8 M).

Total Revenue

Total revenue comprises all receipts Repro Med Systems generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Repro Med Systems minus its cost of goods sold. It is profit before Repro Med operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Repro Med Systems. It is also known as Repro Med overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Net Interest Income

The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.
Most accounts from Repro Med's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Repro Med Systems current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
At present, Repro Med's Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 16.6 M, whereas Operating Income is projected to grow to (9.8 M).
 2021 2022 2023 2024 (projected)
Gross Profit13.8M15.4M15.8M16.6M
Total Revenue23.5M27.9M28.5M29.9M

Repro Med income statement Correlations

0.020.890.840.95-0.88-0.750.95-0.730.930.94-0.880.15-0.940.60.770.560.88-0.870.910.85-0.81-0.810.23
0.020.350.430.120.120.47-0.070.480.230.070.12-0.930.13-0.090.14-0.11-0.090.11-0.05-0.030.130.13-0.05
0.890.350.990.96-0.78-0.540.82-0.520.990.93-0.78-0.21-0.770.30.870.240.63-0.650.680.74-0.55-0.550.31
0.840.430.990.92-0.71-0.440.75-0.420.960.89-0.71-0.3-0.690.270.840.210.56-0.580.620.68-0.49-0.490.3
0.950.120.960.92-0.93-0.760.94-0.750.991.0-0.930.06-0.90.330.90.290.73-0.760.770.84-0.64-0.640.38
-0.880.12-0.78-0.71-0.930.93-0.970.92-0.86-0.951.0-0.330.96-0.28-0.85-0.27-0.740.79-0.77-0.880.630.63-0.42
-0.750.47-0.54-0.44-0.760.93-0.871.0-0.65-0.80.93-0.650.89-0.27-0.68-0.27-0.680.72-0.69-0.780.60.6-0.41
0.95-0.070.820.750.94-0.97-0.87-0.860.890.95-0.970.26-0.990.480.780.460.87-0.890.890.89-0.77-0.770.26
-0.730.48-0.52-0.42-0.750.921.0-0.86-0.63-0.790.92-0.670.88-0.25-0.67-0.25-0.670.71-0.67-0.770.590.59-0.42
0.930.230.990.960.99-0.86-0.650.89-0.630.97-0.86-0.08-0.840.330.890.280.69-0.730.740.8-0.61-0.610.32
0.940.070.930.891.0-0.95-0.80.95-0.790.97-0.950.12-0.920.320.90.280.73-0.760.780.85-0.65-0.650.4
-0.880.12-0.78-0.71-0.931.00.93-0.970.92-0.86-0.95-0.320.95-0.28-0.85-0.26-0.740.8-0.77-0.880.630.63-0.4
0.15-0.93-0.21-0.30.06-0.33-0.650.26-0.67-0.080.12-0.32-0.330.160.010.180.25-0.210.210.21-0.28-0.280.28
-0.940.13-0.77-0.69-0.90.960.89-0.990.88-0.84-0.920.95-0.33-0.55-0.75-0.54-0.90.9-0.92-0.910.80.8-0.26
0.6-0.090.30.270.33-0.28-0.270.48-0.250.330.32-0.280.16-0.550.040.990.84-0.680.820.46-0.84-0.84-0.28
0.770.140.870.840.9-0.85-0.680.78-0.670.890.9-0.850.01-0.750.040.00.47-0.550.530.84-0.29-0.290.49
0.56-0.110.240.210.29-0.27-0.270.46-0.250.280.28-0.260.18-0.540.990.00.83-0.670.810.44-0.84-0.84-0.3
0.88-0.090.630.560.73-0.74-0.680.87-0.670.690.73-0.740.25-0.90.840.470.83-0.921.00.79-0.94-0.94-0.01
-0.870.11-0.65-0.58-0.760.790.72-0.890.71-0.73-0.760.8-0.210.9-0.68-0.55-0.67-0.92-0.93-0.820.810.810.18
0.91-0.050.680.620.77-0.77-0.690.89-0.670.740.78-0.770.21-0.920.820.530.811.0-0.930.81-0.93-0.930.01
0.85-0.030.740.680.84-0.88-0.780.89-0.770.80.85-0.880.21-0.910.460.840.440.79-0.820.81-0.57-0.570.24
-0.810.13-0.55-0.49-0.640.630.6-0.770.59-0.61-0.650.63-0.280.8-0.84-0.29-0.84-0.940.81-0.93-0.571.0-0.01
-0.810.13-0.55-0.49-0.640.630.6-0.770.59-0.61-0.650.63-0.280.8-0.84-0.29-0.84-0.940.81-0.93-0.571.0-0.01
0.23-0.050.310.30.38-0.42-0.410.26-0.420.320.4-0.40.28-0.26-0.280.49-0.3-0.010.180.010.24-0.01-0.01
Click cells to compare fundamentals

Repro Med Account Relationship Matchups

Repro Med income statement Accounts

201920202021202220232024 (projected)
Depreciation And Amortization340.2K418.6K463.1K587.1K870.4K913.9K
Interest Expense6.7M4.8M637.2K145.6K167.4K159.1K
Total Revenue23.2M24.2M23.5M27.9M28.5M29.9M
Gross Profit14.9M14.9M13.8M15.4M15.8M16.6M
Other Operating Expenses19.2M23.0M30.5M38.7M38.8M40.7M
Operating Income585.7K(1.3M)(7.0M)(10.8M)(10.3M)(9.8M)
Ebit7.4M3.6M(7.0M)(10.7M)(10.3M)(9.8M)
Research Development740.5K1.3M2.5M5.0M5.7M6.0M
Ebitda7.7M4.0M(6.5M)(10.2M)(9.4M)(8.9M)
Cost Of Revenue8.3M9.2M9.7M12.5M12.7M13.3M
Total Operating Expenses10.9M13.7M20.8M26.1M26.1M27.4M
Income Before Tax696.4K(1.2M)(6.4M)(10.7M)(9.8M)(9.3M)
Total Other Income Expense Net(3.4M)(2.4M)652.0K(39.9K)496.4K521.2K
Net Income564.3K(1.2M)(4.6M)(8.7M)(13.7M)(13.1M)
Income Tax Expense132.1K17.8K(1.8M)(2.0M)4.0M4.2M
Selling General Administrative9.8M12.0M17.9M20.6M20.4M10.7M
Tax Provision132.1K17.8K(1.8M)(2.0M)4.0M4.2M
Interest Income80.7K42.4K13.1K145.6K561.3K589.4K
Net Income From Continuing Ops564.3K(1.2M)4.6M(8.7M)(13.7M)(13.1M)
Net Income Applicable To Common Shares564.3K(1.2M)(4.6M)(8.7M)(7.8M)(7.4M)
Net Interest Income80.7K42.4K13.1K145.6K561.3K589.4K
Reconciled Depreciation340.2K418.6K463.1K587.1K870.4K517.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Repro Med Systems is a strong investment it is important to analyze Repro Med's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Repro Med's future performance. For an informed investment choice regarding Repro Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repro Med. If investors know Repro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repro Med listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.66)
Earnings Share
(0.25)
Revenue Per Share
0.674
Quarterly Revenue Growth
0.215
Return On Assets
(0.14)
The market value of Repro Med Systems is measured differently than its book value, which is the value of Repro that is recorded on the company's balance sheet. Investors also form their own opinion of Repro Med's value that differs from its market value or its book value, called intrinsic value, which is Repro Med's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repro Med's market value can be influenced by many factors that don't directly affect Repro Med's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repro Med's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repro Med is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repro Med's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.